The stock of AbCellera Biologics Inc (ABCL) has gone down by -11.31% for the week, with a -17.61% drop in the past month and a 7.01% rise in the past quarter. The volatility ratio for the week is 7.60%, and the volatility levels for the past 30 days are 6.28% for ABCL. The simple moving average for the past 20 days is -9.05% for ABCL’s stock, with a -2.98% simple moving average for the past 200 days.
Is It Worth Investing in AbCellera Biologics Inc (NASDAQ: ABCL) Right Now?
Company’s 36-month beta value is 0.42.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ABCL is 221.93M, and currently, short sellers hold a 8.30% ratio of that floaft. The average trading volume of ABCL on February 24, 2025 was 3.38M shares.
ABCL) stock’s latest price update
The stock price of AbCellera Biologics Inc (NASDAQ: ABCL) has plunged by -4.29 when compared to previous closing price of 3.03, but the company has seen a -11.31% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-02-11 that VANCOUVER, British Columbia–(BUSINESS WIRE)—- $ABCL–AbCellera to Participate at Upcoming Investor Conferences in March.
Analysts’ Opinion of ABCL
The Benchmark Company, on the other hand, stated in their research note that they expect to see ABCL reach a price target of $9. The rating they have provided for ABCL stocks is “Buy” according to the report published on February 22nd, 2024.
KeyBanc Capital Markets gave a rating of “Overweight” to ABCL, setting the target price at $6 in the report published on December 05th of the previous year.
ABCL Trading at -5.80% from the 50-Day Moving Average
After a stumble in the market that brought ABCL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.87% of loss for the given period.
Volatility was left at 6.28%, however, over the last 30 days, the volatility rate increased by 7.60%, as shares sank -15.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.51% lower at present.
During the last 5 trading sessions, ABCL fell by -10.24%, which changed the moving average for the period of 200-days by -28.59% in comparison to the 20-day moving average, which settled at $3.19. In addition, AbCellera Biologics Inc saw -1.02% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ABCL
Current profitability levels for the company are sitting at:
- -9.35 for the present operating margin
- -1.8 for the gross margin
The net margin for AbCellera Biologics Inc stands at -5.33. The total capital return value is set at -0.23. Equity return is now at value -15.55, with -12.10 for asset returns.
Based on AbCellera Biologics Inc (ABCL), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -1.68. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -18.42.
Currently, EBITDA for the company is -192.16 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 24.48. The receivables turnover for the company is 0.52for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.34.
Conclusion
In a nutshell, AbCellera Biologics Inc (ABCL) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
